#Singapore #cancer therapy #ACM Biolabs #ACM-CpG

ACM Biolabs Reports Safety Findings for ACM-CpG Administration in Advanced Cancer Patients

ACM Biolabs, a clinical-stage biotechnology company focused on advanced immunotherapies utilizing nanoparticle technology, has released preliminary results from its ongoing phase 1 trial of ACM-CpG. This trial, conducted in partnership with the National Cancer Centre Singapore (NCCS), intends to evaluate the safety, tolerability, and pharmacodynamics of intramuscularly administered ACM-CpG in patients with advanced solid tumors.

The promising data from early clinical findings suggest that ACM-CpG can trigger a robust immune response in patients, as demonstrated by immune biomarker data. In particular, patients receiving doses as low as 0.25 mg of ACM-CpG, whether weekly or biweekly, exhibited significant systemic immune activation without any treatment-limiting toxicities reported thus far.

Dr. Madhavan Nallani, CEO of ACM Biolabs, emphasized the importance of TLR9 as an established immunological target but noted that its therapeutic potential had been limited by safety and administration challenges. Dr. Nallani stated, "Our intramuscular nanoparticle administration facilitates systemic immune activation with an excellent safety profile, paving the way for both combination approaches and targeted monotherapy for patients lacking treatment options. In the future, this platform may also support additional administration routes, enabling adaptation of treatment strategies to various tumor environments and addressing significant unmet medical needs."

The trial has enrolled patients with advanced solid tumors, covering cancers of the head and neck, lung, bladder, and kidney. These investigations aim to substantiate the mechanism underlying the observed pharmacodynamic effects, potentially leading to broader clinical applications of ACM-CpG.

Dr. Amit Jain, Senior Consultant at NCCS’s Medical Oncology Division, expressed optimism regarding the early results. "We are encouraged by the safety profile and evident pharmacodynamic activity observed so far; two out of three enrolled patients at the 0.25 mg dosage maintained disease control for eight months under monotherapy. We look forward to exploring ways to optimize its administration and maximize its therapeutic potential."

The research is partially funded by the Singapore Industry Alignment Fund - Prepositioning (IAF-PP), encouraging strategic collaboration between industry and research institutes.

About ACM Biolabs

ACM Biolabs is headquartered in Singapore, with additional offices in Basel, Switzerland, and Sydney, Australia. The firm specializes in developing targeted vaccines and immunotherapies through its proprietary hybrid nanoparticle delivery platform. ACM Biolabs boasts a diverse product pipeline comprising candidates for oncology, infectious diseases, and inflammation, with a particular focus on precision immune modulation and next-generation drug delivery.

For more details about the study, researchers can visit the clinical trials registry.